Internal Medicine, Gastroenterology · Nashville, TN
NPI
1891011896
Since 2010
Specialty
Internal Medicine, Gastroenterology
Code 207RG0100X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
719 Thompson Ln Ste 20500
Nashville, TN, 37204
Phone (615) 322-0128
Groups this clinician bills Medicare through
Medicare paid, 2024
$24K
242 services
Medicare patients, 2024
148
Average age 68
Drug cost, 2024
$4.7M
675 prescriptions
Company payments, 2025
$6,748
From 5 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Robin L Dalal was code 45380 (lower gi endoscopy - other), 61 times for 57 patients. In total Robin L Dalal billed 242 services in 27 codes, and Medicare paid $24K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-07-21.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 45380 Lower GI Endoscopy - Other | Office | 61 | 57 | $101.85 | $6,213 |
| 45385 Colonoscopy - Lesion Removal | Office | 33 | 33 | $178.35 | $5,886 |
| 99214 Office E&M - Established | Office | 29 | 26 | $74.24 | $2,153 |
| 99215 Office E&M - Established | Office | 21 | 16 | $95.13 | $1,998 |
| 99222 Hospital E&M - Initial | Facility | 14 | 14 | $94.19 | $1,319 |
By year: 2022 $29K for 299 services; 2023 $26K for 261 services; 2024 $24K for 242 services.
Medicare prescription drug claims, 2024
In 2024, the drug Robin L Dalal prescribed most often to Medicare patients was Stelara (Ustekinumab), with 94 prescriptions and refills. In total Robin L Dalal wrote 675 Medicare prescriptions that cost $4.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Stelara Ustekinumab | 94 | 131 | 14 | $2.5M |
| Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl | 77 | 77 | 76 | $1,083 |
| Skyrizi On-Body Risankizumab-Rzaa | 50 | 85 | 15 | $960K |
| Rinvoq Upadacitinib | 37 | 37 | Under 11 | $287K |
| Peg-3350 And Electrolytes Peg3350/Sod Sulf,bicarb,cl/Kcl | 35 | 35 | 33 | $480 |
| Xeljanz Tofacitinib Citrate | 33 | 33 | Under 11 | $182K |
| Omeprazole Generic | 29 | 85 | 14 | $550 |
| Humira(Cf) Pen Adalimumab | 25 | 25 | Under 11 | $271K |
| Diphenoxylate-Atropine Diphenoxylate Hcl/Atropine | 22 | 22 | Under 11 | $660 |
| Entyvio Vedolizumab | 21 | 21 | Under 11 | $185K |
| Ondansetron Odt Ondansetron | 18 | 20 | Under 11 | $647 |
| Mesalamine Er Mesalamine | 18 | 46 | Under 11 | $5,788 |
| Mesalamine Generic | 14 | 24 | Under 11 | $6,337 |
| Humira(Cf) Adalimumab | 13 | 13 | Under 11 | $181K |
| Dicyclomine Hcl Generic | 13 | 15 | Under 11 | $405 |
Brand drugs: 371 claims; generic drugs: 304 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Robin L Dalal $6,748 ($6,748 in general payments such as food, travel and fees) from 5 companies. The largest payer was Abbvie Inc. with $6,386.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.